AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36116866 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-pyloric feeding tube location
Number of subjects: 283
Study 36116866 — intervention group
Group type: EXPERIMENTAL
Intervention: Abundant microaspiration (positive pepsin A ≥ 6.25 ng/mL)
Number of subjects: 283
Study 36116866 — intervention group
Group type: COMPARATOR
Intervention: No enteral feeding
Number of subjects: 283
Study 36117003 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273)
Number of subjects: 8000
Study 36117003 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA COVID-19 vaccines
Number of subjects: 8000
Study 36117003 — intervention group
Group type: COMPARATOR
Intervention: mRNA-1273
Number of subjects: 8000
Study 36117166 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-direct-acting antiviral agent HCC
Number of subjects: 530
Study 36117166 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating lymphocytes
Number of subjects: 530
Study 36117166 — intervention group
Group type: EXPERIMENTAL
Intervention: HCC variants
Number of subjects: 530
Study 36117166 — intervention group
Group type: EXPERIMENTAL
Intervention: Old age, male gender, elevated alpha-fetoprotein level, tumor size, and background liver
Number of subjects: 530
Study 36117179 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson stress myocardial contrast echocardiography (MCE)
Number of subjects: 32
Study 36117179 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 32
Study 36117179 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal myectomy (in 3 patients)
Number of subjects: 32
Study 36117330 — intervention group
Group type: EXPERIMENTAL
Intervention: Low testosterone (LT) group
Number of subjects: 68
Study 36117330 — intervention group
Group type: COMPARATOR
Intervention: Normal testosterone (NT) group
Number of subjects: 68
Study 36117519 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver elastography
Number of subjects: 31
Study 36117519 — intervention group
Group type: EXPERIMENTAL
Intervention: Spleen elastography
Number of subjects: 31
Study 36117519 — intervention group
Group type: COMPARATOR
Intervention: Changes in HVPG results
Number of subjects: 31
Study 36117973 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dexmedetomidine (0.1 to 0.2 μg/kg/h)
Number of subjects: 80
Study 36117973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 36118431 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP) plus standard intervention
Number of subjects: 42
Study 36118431 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (standard care)
Number of subjects: 42
Study 36118751 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened soda (1 L/day)
Number of subjects: 0
Study 36118751 — intervention group
Group type: COMPARATOR
Intervention: Semi-skimmed milk
Number of subjects: 0
Study 36118751 — intervention group
Group type: COMPARATOR
Intervention: Aspartame-sweetened soda
Number of subjects: 0
Study 36118751 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study 36119522 — intervention group
Group type: EXPERIMENTAL
Intervention: mDCF (docetaxel 40 mg/m², cisplatin, and 5-fluorouracil) followed by chemoradiotherapy
Number of subjects: 0
Study 36119552 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal circuit exercise
Number of subjects: 164
Study 36119552 — intervention group
Group type: COMPARATOR
Intervention: Cycle of multidisciplinary lectures on pain and stretching exercise
Number of subjects: 164
Study 36119641 — intervention group
Group type: EXPERIMENTAL
Intervention: cCRT (concurrent chemoradiotherapy)
Number of subjects: 3151
Study 36119641 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR-TKI monotherapy
Number of subjects: 3151
Study 36119669 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin A (BoNT-A) treatment
Number of subjects: 30
Study 36119746 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learned algorithm
Number of subjects: 230
Study 36119770 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 86
Study 36119770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 36119787 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir combined with ledipasvir (SOF/LDV)
Number of subjects: 0
Study 36119787 — intervention group
Group type: COMPARATOR
Intervention: Simeprevir with pegylated interferon plus ribavirin (Sim+IFN)
Number of subjects: 0
Study 36120090 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine (30 μg), administered in two doses intramuscularly, 21 days apart
Number of subjects: 959
Study 36120090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 959
Study 36120713 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized digital intervention based on social rhythm regulation principles
Number of subjects: 133
Study 36120713 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard outpatient treatment)
Number of subjects: 133
Study 36120850 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage radiation therapy (sRT) with or without 2 years of Bicalutamide
Number of subjects: 421
Study 36120850 — intervention group
Group type: EXPERIMENTAL
Intervention: Early sBCR
Number of subjects: 421
Study 36120850 — intervention group
Group type: COMPARATOR
Intervention: Late sBCR
Number of subjects: 421
Study 36121014 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional stenting
Number of subjects: 430
Study 36121244 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacomechanical catheter-directed thrombolysis (PM-CDT) using the Bashir endovascular catheter with 7 mg tPA infused over 5 hours.
Number of subjects: 109
Study 36121499 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (EC-ASA)
Number of subjects: 42
Study 36121499 — intervention group
Group type: COMPARATOR
Intervention: Plain aspirin (P-ASA)
Number of subjects: 42
Study 36121499 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EC-ASA and P-ASA
Number of subjects: 42
Study 36121707 — intervention group
Group type: EXPERIMENTAL
Intervention: ARP strategy (LSM < 1.805 m/s or SSM < 2.445 m/s and PLT > 110 × 10^9/L)
Number of subjects: 741
Study 36121707 — intervention group
Group type: COMPARATOR
Intervention: Baveno VI criteria
Number of subjects: 741
Study 36121803 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit Charge 3 activity tracker
Number of subjects: 27
Study 36122315 — intervention group
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 796
Study 36122888 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit drug identification through combined skin testing, in vitro testing, or drug provocation tests.
Number of subjects: 357
Study 36122968 — intervention group
Group type: EXPERIMENTAL
Intervention: FaCES intervention
Number of subjects: 1226
Study 36122968 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 1226
Study 36123064 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid for Lung Cancer Molecular Testing (DA_LCMT)
Number of subjects: 0
Study 36123064 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured interviews with qualitative research methods
Number of subjects: 0
Study 36123064 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive statistics
Number of subjects: 0
Study 36123064 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data analysis using grounded theory
Number of subjects: 0
Study 36123069 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid serological test targeting IgM and IgG against the receptor binding domain of SARS-CoV-2
Number of subjects: 3648
Study 36123069 — intervention group
Group type: COMPARATOR
Intervention: Not vaccinated participants
Number of subjects: 3648
Study 36123069 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination
Number of subjects: 3648
Study 36123070 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma confirmed through diagnostic tests (spirometry, fraction of exhaled nitric oxide, blood eosinophil count) and patient-reported outcome measures.
Number of subjects: 15000
Study 36123070 — intervention group
Group type: EXPERIMENTAL
Intervention: Further evaluation of patients with asthma, difficult-to-treat asthma, and severe asthma after 3 months.
Number of subjects: 15000
Study 36123081 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive and brief electronic multiple behaviour change intervention with individualised and motivation-enhancing computer-generated feedback at months 0, 1, and 3.
Number of subjects: 175
Study 36123081 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive and brief electronic multiple behaviour change intervention.
Number of subjects: 175
Study 36123124 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PSV and carotid plaques (CPs)
Number of subjects: 2623
Study 36123169 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid vaccines
Number of subjects: 0
Study 36123169 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 vaccines
Number of subjects: 0
Study 36123234 — intervention group
Group type: EXPERIMENTAL
Intervention: CRISPR-Cas9-based genome editing
Number of subjects: 0
Study 36123540 — intervention group
Group type: EXPERIMENTAL
Intervention: Full peritoneal penetration with tumor cells on the peritoneal surface (n=89)
Number of subjects: 189
Study 36123540 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-99 µm distance to the peritoneal surface (n=34)
Number of subjects: 189
Study 36123540 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-999 µm distance to the peritoneal surface (n=33)
Number of subjects: 189
Study 36123540 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥1000 µm distance to the peritoneal surface (n=33)
Number of subjects: 189
Study 36123697 — intervention group
Group type: EXPERIMENTAL
Intervention: TransCon TLR7/8 Agonist
Number of subjects: 0
Study 36123761 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART portal (digital therapeutic self-management tool)
Number of subjects: 22
Study 36123771 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalized children (137 participants)
Number of subjects: 137
Study 36123771 — intervention group
Group type: COMPARATOR
Intervention: Community children (84 participants)
Number of subjects: 137
Study 36124180 — intervention group
Group type: EXPERIMENTAL
Intervention: HLX04-O intravitreal injections at a dose of 1.25 mg/0.05 mL every four weeks
Number of subjects: 1
Study 36124180 — intervention group
Group type: EXPERIMENTAL
Intervention: HLX04-O intravitreal injections
Number of subjects: 1
Study 36124294 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin/Ezetimibe (Trezete®)
Number of subjects: 103
Study 36124629 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimiralisib
Number of subjects: 8
Study 36124645 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto-vegetarian diet
Number of subjects: 30000
Study 36124645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovolacto-vegetarian diet
Number of subjects: 30000
Study 36124645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pescovegetarian diet
Number of subjects: 30000
Study 36124645 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-meat diet
Number of subjects: 30000
Study 36124645 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-meat diet
Number of subjects: 30000
Study 36124645 — intervention group
Group type: EXPERIMENTAL
Intervention: High-meat diet
Number of subjects: 30000
Study 36124645 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian diets
Number of subjects: 30000
Study 36124692 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with angina (n = 931)
Number of subjects: 1770
Study 36124692 — intervention group
Group type: COMPARATOR
Intervention: Women with angina (n = 931) and Women with unspecific chest pain (n = 839)
Number of subjects: 1770
Study 36124767 — intervention group
Group type: EXPERIMENTAL
Intervention: Edge-to-Edge Transcatheter Mitral Valve Repair
Number of subjects: 0
Study 36124767 — intervention group
Group type: COMPARATOR
Intervention: Optimal Medical Treatment
Number of subjects: 0
Study 36124872 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely reperfusion in patients with ST-elevation ACS
Number of subjects: 5107
Study 36124872 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy at discharge
Number of subjects: 5107
Study 36124924 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib 1 mg/day (0.75 mg/day for moderate renal impairment)
Number of subjects: 127
Study 36125017 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol TCI anaesthesia during calibration phase
Number of subjects: 0
Study 36125017 — intervention group
Group type: EXPERIMENTAL
Intervention: NOL index response to a tetanic stimulus under remifentanil antinociception
Number of subjects: 0
Study 36125116 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-computer interface (BCI) used to control a virtual hand, specific details on dosage and duration not available.
Number of subjects: 1
Study 36125208 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen receptor (AR) chromatin binding features
Number of subjects: 0
Study 36125208 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic analyses of AR chromatin binding features
Number of subjects: 0
Study 36125208 — intervention group
Group type: EXPERIMENTAL
Intervention: AR chromatin binding patterns
Number of subjects: 0
Study 36125208 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies on AR cistrome
Number of subjects: 0
Study 36125208 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of therapeutic targets
Number of subjects: 0
Study 36125263 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab + Metformin
Number of subjects: 0
Study 36125263 — intervention group
Group type: COMPARATOR
Intervention: Durvalumab alone
Number of subjects: 0
Study 36125263 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV+ samples
Number of subjects: 0
Study 36125263 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic responders
Number of subjects: 0
Study 36125279 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg
Number of subjects: 5
Study 36125279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant 100 mg
Number of subjects: 5
Study 36125279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant 25 mg
Number of subjects: 5
Study 36125279 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg
Number of subjects: 5
Study 36125279 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 5
Study 36125279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 36125352 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive involvement behaviors during trauma narration
Number of subjects: 65
Study 36125352 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative involvement behaviors during trauma narration
Number of subjects: 65
Study 36125352 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger alliance
Number of subjects: 65
Study 36125352 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-related self-disclosure
Number of subjects: 65
Study 36125356 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatix Severity 2 classifier
Number of subjects: 397
Study 36125356 — intervention group
Group type: COMPARATOR
Intervention: Lactate
Number of subjects: 397
Study 36125356 — intervention group
Group type: COMPARATOR
Intervention: Procalcitonin
Number of subjects: 397
Study 36125356 — intervention group
Group type: COMPARATOR
Intervention: qSOFA
Number of subjects: 397
Study 36125356 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of qSOFA and IMX-SEV-2
Number of subjects: 397
Study 36125356 — intervention group
Group type: EXPERIMENTAL
Intervention: High-severity (rule-in) interpretation band of IMX-SEV-2
Number of subjects: 397
Study 36125356 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-severity (rule-out) band of IMX-SEV-2
Number of subjects: 397
Study 36125356 — intervention group
Group type: EXPERIMENTAL
Intervention: IMX-SEV-2
Number of subjects: 397
Study 36125356 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IMX-SEV-2 and qSOFA
Number of subjects: 397
Study 36125366 — intervention group
Group type: EXPERIMENTAL
Intervention: BA.2 breakthrough infection in triple-immunized individuals
Number of subjects: 0
Study 36125366 — intervention group
Group type: EXPERIMENTAL
Intervention: BA.2 convalescent sera
Number of subjects: 0
Study 36125366 — intervention group
Group type: EXPERIMENTAL
Intervention: Omicron BA.1 convalescent sera
Number of subjects: 0
Study 36125366 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to Omicron BA.2
Number of subjects: 0
Study 36125379 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-field-strength MRI in children and adolescents with post-COVID-19 condition
Number of subjects: 54
Study 36125855 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceset digital peer support intervention (n=50 seekers, n=30 befrienders, n=30 moderators) for 3 weeks
Number of subjects: 100
Study 36125855 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group (n=50)
Number of subjects: 100
Study 36126069 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraspinal pressure monitoring using a fiberoptic pressure monitor
Number of subjects: 20
Study 36126069 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of physiological parameters including spinal cord perfusion pressure, spinal cord blood volume, spinal cord compliance, and vascular reactivity indices
Number of subjects: 20
Study 36126109 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTA parameters in moderate-advanced glaucoma
Number of subjects: 144
Study 36126109 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTA parameters in early glaucoma
Number of subjects: 144
Study 36126126 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial T1 mapping
Number of subjects: 1576
Study 36126126 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular volume fraction (ECV) measurement
Number of subjects: 1576
Study 36126126 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial T2 mapping
Number of subjects: 1576
Study 36126143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation for AF in patients with HFpEF
Number of subjects: 102
Study 36126143 — intervention group
Group type: COMPARATOR
Intervention: Cryoballoon ablation for AF in patients without HFpEF
Number of subjects: 102
Study 36126298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill adherence
Number of subjects: 0
Study 36126315 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression therapy, details on dosage and duration not available.
Number of subjects: 0
Study 36126902 — intervention group
Group type: COMPARATOR
Intervention: Synbiotics
Number of subjects: 250
Study 36126902 — intervention group
Group type: COMPARATOR
Intervention: Probiotics
Number of subjects: 250
Study 36127090 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric MRI combined with liquid biopsies
Number of subjects: 100
Study 36127090 — intervention group
Group type: COMPARATOR
Intervention: Standard clinico-pathological information
Number of subjects: 100
Study 36127228 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination
Number of subjects: 1076
Study 36127539 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Specialists (PSs) integration in primary care settings
Number of subjects: 52
Study 36127539 — intervention group
Group type: COMPARATOR
Intervention: External facilitation
Number of subjects: 52
Study 36127713 — intervention group
Group type: EXPERIMENTAL
Intervention: e-EQ-5D-5L/VAS
Number of subjects: 665
Study 36127767 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemigatinib 13.5 mg oral once daily (3-week cycle; 2 weeks on, 1 week off)
Number of subjects: 31
Study 36127770 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-derived cell-free DNA (dd-cfDNA) monitoring
Number of subjects: 0
Study 36127770 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial dd-cfDNA determination
Number of subjects: 0
Study 36127853 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (cALND) omission
Number of subjects: 1421
Study 36127853 — intervention group
Group type: COMPARATOR
Intervention: Completion axillary lymph node dissection (cALND)
Number of subjects: 1421
Study 36127922 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 126
Study 36128334 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab plus standard-of-care
Number of subjects: 116
Study 36128334 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard-of-care
Number of subjects: 116
Study 36128334 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 116
Study 36128334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 36129032 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase at 0.6 mg/kg
Number of subjects: 915
Study 36129032 — intervention group
Group type: COMPARATOR
Intervention: No oral anticoagulants
Number of subjects: 915
Study 36129046 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Work Index (GWI) measurement in patients with elevated troponin (n=71)
Number of subjects: 305
Study 36129046 — intervention group
Group type: EXPERIMENTAL
Intervention: GWI measurement in relation to disease severity and all-cause death
Number of subjects: 305
Study 36129052 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered stent deployment
Number of subjects: 43343
Study 36129052 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural major adverse cardiac events
Number of subjects: 43343
Study 36129273 — intervention group
Group type: EXPERIMENTAL
Intervention: MMA embolization
Number of subjects: 322
Study 36129273 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor Xa inhibitor use
Number of subjects: 322
Study 36129459 — intervention group
Group type: EXPERIMENTAL
Intervention: VB10.16
Number of subjects: 34
Study 36129471 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus eribulin
Number of subjects: 30
Study 36129579 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-follicular phase (EFP)
Number of subjects: 21
Study 36129579 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-follicular phase (LFP)
Number of subjects: 21